Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TriMaster third-line therapy crossover study in type 2 diabetes
2015-002790-38Phase 4Unknown
- Sponsor
- Royal Devon University Healthcare NHS Foundation Trust
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of pioglitazone, sitagliptin and canagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Royal Devon University Healthcare NHS Foundation Trust. Primary endpoint: HbA1c on treatment after 16 weeks. Status: unknown.
02
Drugs
pioglitazonesitagliptincanagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-002790-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002790-38.